Meningococcal burden of disease in Argentina: 10 years epidemiologic review.
Argentina
Children
disease burden
meningococcal disease
serogroups
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
01 08 2023
01 08 2023
Historique:
medline:
25
8
2023
pubmed:
24
8
2023
entrez:
24
8
2023
Statut:
ppublish
Résumé
Invasive meningococcal disease (IMD) is an uncommon but serious and potentially fatal condition, mainly affecting infants. In 2017, Argentina introduced a vaccination program against serogroups A, C, W and Y (MenACWY) for infants aged 3, 5 and 15 months and adolescents aged 11 years. The objective of this study was to review the burden of IMD in Argentina in 2010-2019. Data were obtained from national surveillance databases, and the study estimated IMD incidence, mortality, case-fatality rates, and serogroup distributions across age groups. A total of 1,972 IMD cases were reported in the study period, with the highest incidence in infants aged < 1 year. Incidence peaked in 2013 and subsequently declined. Mortality rates were 18 times higher in infants than in other age groups, reflecting the high impact of IMD in this age group. The case-fatality rate was 8.5% on average and increased with age. The proportion of notified cases with serogroup identification increased over the period, reaching 91% in 2019. The most common serogroups over the study period were serogroup B (48%) and serogroup W (42%), with an increase in B relative to W since 2015. In infants aged < 1 year, the proportion of serogroup B increased in recent years, reaching around 70% of characterized cases in 2018-2019. These results show the dynamism of IMD and indicate the importance of vaccination at an early age and offering protection against predominant serogroups. These data are valuable to support evidence-based decision-making in healthcare.
Identifiants
pubmed: 37614151
doi: 10.1080/21645515.2023.2237391
pmc: PMC10453991
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2237391Références
J Adolesc Health. 2016 Aug;59(2 Suppl):S3-S11
pubmed: 27449148
Rev Med Chil. 2013 Aug;141(8):959-67
pubmed: 24448851
Microbiology (Reading). 2002 Jun;148(Pt 6):1813-1819
pubmed: 12055301
Vaccine. 2019 May 9;37(21):2768-2782
pubmed: 30987851
Popul Health Metr. 2013 Sep 10;11(1):17
pubmed: 24016339
Wkly Epidemiol Rec. 2011 Nov 18;86(47):521-39
pubmed: 22128384
J Clin Microbiol. 2004 Apr;42(4):1764-5
pubmed: 15071043
Infect Dis Ther. 2018 Dec;7(4):421-438
pubmed: 30267220
Pediatr Infect Dis J. 2017 Mar;36(3):296-300
pubmed: 27902653
PLoS One. 2011;6(6):e20675
pubmed: 21731621
Rev Panam Salud Publica. 2017 Dec 20;41:e118
pubmed: 31391828
Epidemiol Infect. 2019 Nov 29;147:e311
pubmed: 31779718
BMC Public Health. 2022 Feb 23;22(1):380
pubmed: 35197024
J Clin Microbiol. 2000 Feb;38(2):855-7
pubmed: 10655397
Hum Vaccin Immunother. 2023 Dec 31;19(1):2186111
pubmed: 37017273
Int J Infect Dis. 2019 Aug;85:37-48
pubmed: 31085314
Vaccine. 2019 Oct 31;37(46):6915-6921
pubmed: 31585728